The rise of fentanyl and other synthetic opioids is unlike any drug crisis in U.S. history. Limiting policy responses to existing approaches will likely be insufficient and may condemn many people to early deaths.
This paper is the first to examine cannabis market data from Washington alongside that from Oregon, two states that are similar in regard to legalizing retail sales of cannabis but differ in terms of their regulatory frameworks.
This report documents an analysis of the performance of U.S. Army recruits who receive waivers, as well as those with a documented history of marijuana, attention-deficit/hyperactivity disorder, depression, or anxiety.
This retrospective analysis examines filled naloxone prescriptions among patients receiving buprenorphine treatment and assesses how rates of filled naloxone prescriptions varies by patient, prescriber, and community characteristics.
We analyze substance use, AI/AN cultural identity and involvement, physical health and cognitive functioning, and mental health symptoms among 63 AI/AN adults seeking substance use treatment within an urban area in California.
This cross-sectional study examined how transaction sales limits on recreational cannabis translate to tetrahydrocannabinol doses among U.S. states allowing commercial cannabis sales as of January 1, 2020.
This study identifies distinct patterns (classes) of substance use among 30- to 80-year olds, identifies demographic subgroups with the highest probability of class memberships, and compares classes on key indicators of functioning.
More than 2,000 plaintiffs have joined the largest civil trial in U.S. history: National Prescription Opiate Litigation (MDL 2804). In this virtual symposium, experts discuss the opioid litigation and its effects on the future of mass litigation.
In this RAND Remote presentation, Beau Kilmer discusses how RAND is identifying and evaluating innovative approaches to tackle some of America's most pressing drug problems and help strengthen and safeguard communities.